Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm.
Aminopropionitrile
Angiotensin II
Animals
Anti-Inflammatory Agents
/ pharmacology
Aorta, Abdominal
/ drug effects
Aortic Aneurysm, Abdominal
/ chemically induced
Case-Control Studies
Cell Adhesion
/ drug effects
Cells, Cultured
Disease Models, Animal
Dynamins
/ genetics
Humans
Leukocytes
/ drug effects
Male
Mice, Inbred C57BL
Mice, Knockout, ApoE
Mitochondria, Muscle
/ drug effects
Mitochondrial Dynamics
/ drug effects
Muscle, Smooth, Vascular
/ drug effects
Myocytes, Smooth Muscle
/ drug effects
Oxygen Consumption
/ drug effects
Phosphorylation
Quinazolinones
/ pharmacology
Abdominal aortic aneurysm
Inflammation
Mitochondria
Senescence
Vascular smooth muscle cell
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
22 02 2021
22 02 2021
Historique:
received:
27
11
2019
revised:
15
04
2020
accepted:
30
04
2020
pubmed:
10
5
2020
medline:
5
1
2022
entrez:
9
5
2020
Statut:
ppublish
Résumé
Angiotensin II (AngII) is a potential contributor to the development of abdominal aortic aneurysm (AAA). In aortic vascular smooth muscle cells (VSMCs), exposure to AngII induces mitochondrial fission via dynamin-related protein 1 (Drp1). However, pathophysiological relevance of mitochondrial morphology in AngII-associated AAA remains unexplored. Here, we tested the hypothesis that mitochondrial fission is involved in the development of AAA. Immunohistochemistry was performed on human AAA samples and revealed enhanced expression of Drp1. In C57BL6 mice treated with AngII plus β-aminopropionitrile, AAA tissue also showed an increase in Drp1 expression. A mitochondrial fission inhibitor, mdivi1, attenuated AAA size, associated aortic pathology, Drp1 protein induction, and mitochondrial fission but not hypertension in these mice. Moreover, western-blot analysis showed that induction of matrix metalloproteinase-2, which precedes the development of AAA, was blocked by mdivi1. Mdivi1 also reduced the development of AAA in apolipoprotein E-deficient mice infused with AngII. As with mdivi1, Drp1+/- mice treated with AngII plus β-aminopropionitrile showed a decrease in AAA compared to control Drp1+/+ mice. In abdominal aortic VSMCs, AngII induced phosphorylation of Drp1 and mitochondrial fission, the latter of which was attenuated with Drp1 silencing as well as mdivi1. AngII also induced vascular cell adhesion molecule-1 expression and enhanced leucocyte adhesion and mitochondrial oxygen consumption in smooth muscle cells, which were attenuated with mdivi1. These data indicate that Drp1 and mitochondrial fission play salient roles in AAA development, which likely involves mitochondrial dysfunction and inflammatory activation of VSMCs.
Identifiants
pubmed: 32384150
pii: 5834715
doi: 10.1093/cvr/cvaa133
pmc: PMC7898955
doi:
Substances chimiques
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone
0
Anti-Inflammatory Agents
0
Quinazolinones
0
Angiotensin II
11128-99-7
Aminopropionitrile
151-18-8
DNM1L protein, human
EC 3.6.5.5
Dnm1l protein, mouse
EC 3.6.5.5
Dynamins
EC 3.6.5.5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
971-982Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL128324
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS109382
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL133248
Pays : United States
Organisme : NHLBI NIH HHS
ID : F30 HL146006
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK111042
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
Références
Circ Res. 2016 Jun 10;118(12):1960-91
pubmed: 27126807
Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1660-5
pubmed: 19252100
Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):127-36
pubmed: 25378412
Aging Cell. 2015 Feb;14(1):1-7
pubmed: 25399755
Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345
pubmed: 27889204
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2191-2202
pubmed: 27634836
Lancet. 2005 Apr 30-May 6;365(9470):1577-89
pubmed: 15866312
Dev Cell. 2008 Feb;14(2):193-204
pubmed: 18267088
J Mol Cell Cardiol. 2018 Aug;121:103-106
pubmed: 29981304
Circ Res. 2019 Feb 15;124(4):607-618
pubmed: 30763207
Redox Biol. 2019 Jun;24:101185
pubmed: 30954686
Hypertension. 2017 Jan;69(1):79-86
pubmed: 27895190
J Mol Cell Cardiol. 2015 Oct;87:152-9
pubmed: 26254182
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2158-2162
pubmed: 27562915
PLoS One. 2012;7(4):e35312
pubmed: 22514726
Hypertens Res. 2001 May;24(3):251-61
pubmed: 11409648
Annu Rev Genet. 2012;46:265-87
pubmed: 22934639
Dev Cell. 2017 Mar 27;40(6):583-594.e6
pubmed: 28350990
Sci Signal. 2018 Nov 13;11(556):
pubmed: 30425165
Clin Sci (Lond). 2014 Jun;126(11):785-94
pubmed: 24329494
Circ Res. 2018 Aug 31;123(6):651-653
pubmed: 30355238
Hypertension. 2017 Nov;70(5):959-963
pubmed: 28947615
Int J Angiol. 2018 Jun;27(2):58-80
pubmed: 29896039
Cell Rep. 2018 Dec 11;25(11):3059-3073.e10
pubmed: 30540939
Clin Sci (Lond). 2012 Nov;123(9):531-43
pubmed: 22788237
Clin Sci (Lond). 2019 Jul 5;133(13):1421-1438
pubmed: 31239294
Hypertension. 2016 Nov;68(5):1245-1254
pubmed: 27572148
Nat Rev Cardiol. 2017 Aug;14(8):457-471
pubmed: 28406184
Am J Pathol. 2014 Nov;184(11):3130-41
pubmed: 25194661
Dev Neurobiol. 2017 Nov;77(11):1260-1268
pubmed: 28842943
Surgery. 2005 Oct;138(4):806-11
pubmed: 16269312
Clin Sci (Lond). 2015 May;128(9):559-65
pubmed: 25531554
Arterioscler Thromb Vasc Biol. 2013 Oct;33(10):2389-96
pubmed: 23950141
Nature. 2014 May 22;509(7501):439-46
pubmed: 24848057
J Cell Biol. 2009 Sep 21;186(6):805-16
pubmed: 19752021
J Cell Biochem. 2015 Apr;116(4):648-60
pubmed: 25399916
J Cardiovasc Pharmacol. 2012 Jan;59(1):66-76
pubmed: 21964156
J Vasc Surg. 2014 Oct;60(4):1033-41; discussion 1041-2
pubmed: 24080131
Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):401-410
pubmed: 28062500
Arterioscler Thromb Vasc Biol. 2015 Sep;35(9):1963-74
pubmed: 26139463
J Surg Res. 2000 Jul;92(1):85-95
pubmed: 10864487
Pharmaceuticals (Basel). 2019 Aug 06;12(3):
pubmed: 31390798
PLoS One. 2017 Jul 6;12(7):e0179743
pubmed: 28683125
Br J Pharmacol. 2014 Apr;171(8):1890-906
pubmed: 24328763
J Immunol. 2013 May 15;190(10):5078-85
pubmed: 23585675
Nat Protoc. 2009;4(10):1513-21
pubmed: 19798084
PLoS One. 2013 Nov 14;8(11):e81743
pubmed: 24244746
Mol Cell. 2015 Feb 5;57(3):537-51
pubmed: 25658205
Circ Res. 2017 Jul 21;121(3):220-233
pubmed: 28607103
PLoS One. 2012;7(10):e48462
pubmed: 23119030
Am J Physiol Cell Physiol. 2018 Jul 1;315(1):C80-C90
pubmed: 29669222
Biochim Biophys Acta. 2014 Aug;1842(8):1179-85
pubmed: 24326103
Circ Res. 2016 Oct 28;119(10):1076-1088
pubmed: 27650558
Cell Rep. 2018 Jun 19;23(12):3565-3578
pubmed: 29924999
Circulation. 2011 Jul 26;124(4):444-53
pubmed: 21747057
Nat Rev Cardiol. 2011 Feb;8(2):92-102
pubmed: 21079638
J Vasc Res. 2016;53(1-2):17-26
pubmed: 27344146
Diabetes. 2017 Jan;66(1):193-205
pubmed: 27737949
Circulation. 2013 Sep 10;128(11 Suppl 1):S163-74
pubmed: 24030402
Physiol Rev. 2018 Jul 1;98(3):1627-1738
pubmed: 29873596
Hypertension. 2010 May;55(5):1267-74
pubmed: 20212272
Aging (Albany NY). 2013 Jan;5(1):37-50
pubmed: 23449538
Biochim Biophys Acta. 2012 Jun;1822(6):862-74
pubmed: 22387883
J Thorac Cardiovasc Surg. 2009 Dec;138(6):1392-9
pubmed: 19931668
Circ Res. 2015 Jan 16;116(2):264-78
pubmed: 25332205
Cardiovasc Res. 2015 May 1;106(2):272-83
pubmed: 25587046
Nat Commun. 2015 Sep 18;6:8371
pubmed: 26381214
PLoS One. 2012;7(12):e51483
pubmed: 23236507